AC-150A 0.1% — Competitive Intelligence Brief

AC-150A 0.1% (AC-150A 0.1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: topical corticosteroid. Area: Dermatology.

phase 2 topical corticosteroid Dermatology Small molecule

Target snapshot

AC-150A 0.1% (AC-150A 0.1%) — Aciex Therapeutics, Inc.. AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AC-150A 0.1% TARGET	AC-150A 0.1%	Aciex Therapeutics, Inc.	phase 2	topical corticosteroid
Halobetasol Topical Foam	Halobetasol Topical Foam	Mayne Pharma International Pty Ltd	marketed	Topical corticosteroid (Class I, super-potent)	Glucocorticoid receptor
Triamcinolone Acetonide 0.1% Oint	Triamcinolone Acetonide 0.1% Oint	Al-Azhar University	marketed	Topical corticosteroid	Glucocorticoid receptor
Prednisone acetate 1%	Prednisone acetate 1%	Kovach Eye Institute	marketed	Topical corticosteroid	Glucocorticoid receptor
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Desoximetasone Spray 0.25%	Desoximetasone Spray 0.25%	Sun Pharmaceutical Industries, Inc.	marketed	Topical corticosteroid	Glucocorticoid receptor
Loteprednol Etabonate 0.5%	Loteprednol Etabonate 0.5%	Federal University of São Paulo	marketed	Topical corticosteroid	Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (topical corticosteroid class)

1. Aciex Therapeutics, Inc. · 2 drugs in this class